

●論文発表（過去5年間）

・細川智成、小武和正、田中増郎. 治療目標に応じたナルメフェンの有効性と安全性についての検討. 日本アルコール・薬物医学会雑誌, 56 (3): 86-96, 2021.

・Hosokawa T, Miyaji C, Yoshimura Y, et al. Comparison between olanzapine and aripiprazole treatment for 104 weeks after hospital discharge in schizophrenia spectrum disorders: a multicenter retrospective cohort study in a real-world setting. *Psychopharmacology (Berl)*. 240(9):1911-1920, 2023.

・Kotake K, Mitsuboshi S, Hosokawa T, Kitamura N, Kawakami Y. Effect of cytochrome P450 1A2 inhibitors on rhabdomyolysis in patients on clozapine: Analysis using the US Food and Drug Administration's Adverse Event Reporting System. *Schizophr Res*. 262:102-103. 2023.

・Kotake K, Hosokawa T, Tanaka M, et al. Efficacy and safety of alcohol reduction pharmacotherapy according to treatment duration in patients with alcohol dependence or alcohol use disorder: A systematic review and network meta-analysis. *Addiction*. 119(5):815-832, 2024.

・小武和正、細川智成、高橋真由美, et al. 総合病院におけるアルコール使用障害患者を対象としたナルメフェンの有効性および安全性に関する検討. *日本総合病院精神医学*. 36(1): 26-34, 2024.

・Kazumasa K, Satoru M, Naoya K, et al. Preventive effects of first-generation antihistamine on emergence agitation or delirium: a systematic review. *European Journal of Clinical Pharmacology*, 80, 1883-1892, 2024.